SAB Biotherapeutics, Inc.

SABS

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
SEC CIK: 0001833214

SEC filings (opens in a new tab)

No open-market purchases or sales by SAB Biotherapeutics, Inc. insiders were filed in the last 90 days; 87 institutions reported holding it in 13F filings for Q2 2026, worth $266.8M in total; no superinvestor holds it.

Other share classesSABSW

Q1 2026 vs. Q4 2025

How the institutions holding SAB Biotherapeutics, Inc. changed between Q4 2025 and Q1 2026.

All holders in Q1 2026 All holders in Q4 2025

13F holders of SABS: Q4 2025 compared with Q1 2026
Measure	Q4 2025	Of which not filed for Q1 2026	Q1 2026	Change
Holders	48	1	76	+29
Shares	36.3M	1.85M	69.2M	+34.7M (+100.6%)
Value	$135.9M	$6.91M	$265.0M	+$136.0M (+105.4%)

1 institution that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so the changes leave them out.

New holders (34)

Institutions that held SAB Biotherapeutics, Inc. at the end of Q1 2026 but not at the end of Q4 2025.

Institutions new to SABS in Q1 2026
Institution	Shares	Value	% of portfolio
Caligan Partners LP	7,967,207	$30.5M	2.16%
Adage Capital Partners GP, L.L.C.	3,405,553	$13.0M	0.02%
Vanguard Capital Management LLC	2,493,737	$9.55M	0.00%
Boothbay Fund Management, LLC	1,481,660	$5.67M	0.13%
Ensign Peak Advisors, Inc	1,375,610	$5.27M	0.01%
Soleus Capital Management, L.P.	1,050,000	$4.02M	0.16%
Affinity Asset Advisors, LLC	575,000	$2.20M	0.13%
Monashee Investment Management LLC	500,000	$1.92M	1.04%
DV Trading LLC	400,000	$1.53M	0.14%
Seven Grand Managers, LLC	275,000	$1.05M	0.07%
Vanguard Fiduciary Trust Co	197,619	$756.9K	0.00%
Two Sigma Investments, LP	181,185	$693.9K	0.00%
Seven Fleet Capital Management LP	100,000	$383.0K	0.12%
Brevan Howard Capital Management LP	59,161	$226.6K	0.00%
Stonepine Capital Management, LLC	50,000	$191.5K	0.17%
Commonwealth Equity Services, LLC	46,455	$177.9K	0.00%
Virtu Financial LLC	37,943	$145.0K	0.01%
American Century Companies Inc	37,455	$143.5K	0.00%
Quadrature Capital Ltd	35,264	$135.1K	0.00%
Prelude Capital Management, LLC	34,124	$130.7K	0.01%
Diametric Capital, LP	16,292	$62.4K	0.02%
Hudson Bay Capital Management LP	16,100	$61.7K	0.00%
Catalyst Funds Management Pty Ltd	15,100	$57.8K	0.01%
Miller Capital Partners, Inc.	12,870	$49.3K	0.02%
Vanguard Global Advisers, LLC	11,852	$45.4K	0.00%
Scientech Research LLC	10,816	$41.4K	0.03%
The PNC Financial Services Group, Inc.	7,700	$29.5K	0.00%
Plante Moran Financial Advisors, LLC	5,925	$22.7K	0.00%
Simplex Trading, LLC	4,713	$18.1K	0.00%
Tower Research Capital LLC (TRC)	3,269	$12.5K	0.00%
BNP Paribas Arbitrage, SA	889	$3.40K	0.00%
Barclays PLC	496	$1.90K	0.00%
Caitong International Asset Management Co., Ltd	161	$617	0.00%
Royal Bank of Canada	1	$0	0.00%

Sold out (5)

Institutions that held SAB Biotherapeutics, Inc. at the end of Q4 2025 and filed for Q1 2026 without it.

Institutions that sold out of SABS in Q1 2026
Institution	Shares, Q4 2025	Value, Q4 2025
Verition Fund Management LLC	26,867	$100.5K
ADAR1 Capital Management, LLC	26,344	$98.5K
Citadel Advisors LLC	17,650	$66.0K
Caxton Corp	10,527	$39.4K
SBI Securities Co., Ltd.	50	$187

Not filed for Q1 2026 yet (1)

Institutions that held SAB Biotherapeutics, Inc. at the end of Q4 2025 and haven't filed a 13F for Q1 2026. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding SABS in Q4 2025 that haven't filed for Q1 2026
Institution	Shares, Q4 2025	Value, Q4 2025
Vanguard Group Inc	1,847,136	$6.91M